Navigation Links
New High Intensity Focused Ultrasound (HIFU) Advances Treatment for Prostate Cancer

NEW YORK, Jan. 26, 2016 /PRNewswire-USNewswire/ -- For the estimated 220,000 men who will be diagnosed with prostate cancer this year, deciding on a method of treatment can be a challenge. Some with early-stage cancer pursue a "wait and watch" option, also called active surveillance, while others with more severe cancer immediately pursue surgery, including prostatectomy (removal of the prostate). Others fall somewhere in the middle. For those men, an exciting new, minimally invasive therapy might be an optimal treatment approach.

High intensity focused ultrasound (HIFU), or focal therapy, is a new concept for treating prostate cancer pioneered by clinician-scientists at NYU Langone Medical Center. The goal is simple: Destroy only the clinically significant cancer within the prostate while sparing adjacent structures and minimizing side effects, such as erectile dysfunction and urinary incontinence.

"This technology provides important treatment for a niche group of men with prostate cancer who otherwise have limited options for care," says Herbert Lepor, MD, the Martin Spatz Chair and Professor of Urology at NYU Langone. "It was rewarding to see our first patient leave our out-patient facility in the afternoon, enjoy dinner with his wife that night, and report no adverse impact on erectile function three days later." 

Earlier this month, Dr. Lepor and colleagues at NYU Langone were the first in the Northeast to utilize Sonablate®, a new focal therapy device, to treat patients with intermediate-risk prostate cancer. Manufactured by SonaCare Medical, Sonablate® uses focused ultrasound energy to destroy prostate tissue at the focal point without harming the tissue around the lesion.  

How HIFU Works

During the HIFU procedure, a diagnostic and therapeutic ultrasound probe is inserted into the rectum under general anesthesia. The surgeons direct the focused ultrasound energy precisely to the cancer under real-time ultrasound guidance, which is co-registered to the original MRI that was used to plan the extent of the tissue ablation. The innovative co-registration fusion software allows the surgeon to ablate the targeted cancerous tissue and a rim of normal tissue, minimizing damage to untargeted tissue.

Upon completion, the surgeon is able to analyze the results in real time using ultrasound imaging and monitoring software that tracks changes in the tissue. Once satisfied with the ablation, the surgeon removes the probe and the patient is transferred to recovery.  

"Building upon our pioneering work in prostate imaging and targeted biopsy, this technology adds an innovative, minimally invasive treatment option to the array of modern treatment choices we can offer our patients," says James Wysock, MD, an assistant professor of urology and a urologic oncologist at NYU Langone certified in HIFU ablation. "We will continue to study this therapy and identify better ways to screen, detect, and treat the disease."

To learn more about the HIFU procedure and other forms of treatment offered at the Smilow Comprehensive Prostate Cancer Center or to schedule an appointment please call 646-754-2400. 

The U.S. Food and Drug Administration approved HIFU therapy for ablation of prostate tissue in the fall of 2015. The procedure is currently not covered by insurance or Medicare. Dr. Lepor owns stock in SonaCare Medical. Dr. Wysock has no disclosure of any commercial interest or financial support from SonaCare Medical.

Media Inquiries:
Rob Magyar


SOURCE NYU Langone Medical Center
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. HIFU Prostate Services Partners with Urology Specialists of the Carolinas and Carolina Urology Partners to Make High Intensity Focused Ultrasound (HIFU) for Prostate Cancer Available in the Carolinas
2. HIFU Prostate Services Launches Operations as Leading Provider of Minimally-Invasive Prostate Cancer Treatments using High Intensity Focused Ultrasound
3. HSRx Groups Acne Treatment Product in Clinical Trial, Aims to Rapidly Reduce Redness and Intensity of Breakouts
4. Researchers Show That Combining Intensity Modulated Radiation Therapy With Chemo-Radiation Offers Long-Term Benefits And Reduced Side Effects For Oropharyngeal Cancer Patients
5. Excellence in High Intensity Focused Ultrasound (HIFU) Outcomes
6. Enterome Announces Collaboration with Johnson & Johnson Innovation Focused on the Discovery of Novel Targets and Therapeutics for Crohns Disease
7. Increasingly Value-Focused US Medical Imaging Market Redefines Vendor-Customer Relationships
8. Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas
9. Essilor Launches New Eyezen Glasses Specifically Designed For A Digital Focused Audience
10. Dauntless Pharmaceuticals Launches New Company Focused on Developing a Portfolio of Improved Therapeutics
11. Acsis Announces White Paper Series Focused on the Use of Serialization in Complex Supply Chain Networks
Post Your Comments:
(Date:6/19/2019)... Pa. (PRWEB) , ... June 19, 2019 , ... ... nuclear receptor and in vitro toxicology testing solutions, announced the addition of the ... kit expands INDIGO’s existing in vitro toxicology offerings and allows researchers to perform ...
(Date:6/18/2019)... ... June 18, 2019 , ... MY ... W Olympic Blvd Suite 350 Los Angeles, CA, 90064, bringing holistic solutions to ... , MY Education Guru has created individual programs to assist students who have ...
(Date:6/18/2019)... ... June 18, 2019 , ... Officials with American Physician ... are pleased to announce the acquisition of Leading Edge Medical Associates (LEMA), a ... physicians and 9 advanced practice clinicians care for 115,000 emergency department patients annually ...
Breaking Medicine Technology:
(Date:6/14/2019)... ... ... reviewed and approved providers for May 2019. , FL TOP DOCS INCLUDE: , BARIATRIC MEDICINE/SURGERY, ... Dr. Debbie Berlin , CARDIOLOGY, Dr. Nirat Beohar ... Dr. Yamilet Tirado , DERMATOLOGY, Dr. B. Jennifer Berkes ...
(Date:6/13/2019)... PETERSBURG, Fla. (PRWEB) , ... June 13, 2019 ... ... and research company today announced that it has signed a memorandum of understanding ... (API) for its drug product MMJ-001 and MMJ-002. , MMJ BioPharma Cultivation will ...
(Date:6/13/2019)... ... 13, 2019 , ... In Partnership with the Smiles for Everyone Foundation ... at its Mesquite, TX office on July 13th. , Dental services provided include same-day ... extractions . For more information, please visit the Monarch Dental website . , ...
(Date:6/13/2019)... ... June 13, 2019 , ... The ... present the second annual Women|Future Conference and the advisory board that ... better position themselves and their organizations in tomorrow's marketplace. , The mission of ...
(Date:6/13/2019)... ... ... Clinical Ink , a global clinical trial technology company that is ... chief business officer at Clinical Ink, has been invited to be a panelist in ... July 1, 2019, in Washington, D.C. The workshop, convened under a cooperative agreement with ...
Breaking Medicine News(10 mins):